Research Nester’s recent market research analysis on “Cancer Biopsy Market: Global Demand Analysis & Opportunity Outlook 2037” delivers a detailed competitor’s analysis and a detailed overview of the global cancer biopsy market in terms of market segmentation by biopsy type, products & services, cancer type, end user, and by region.

Expansion of Research and Development for Early Detection of Multiple Cancer Types

As scientific efforts increasingly prioritize early-stage cancer diagnosis, there is a growing need for advanced biopsy techniques that can accurately cancer biomarkers at the molecular level. This push for early detection has led to the development of innovative biopsy methods, such as liquid biopsies, which are less invasive and can be used for ongoing monitoring of various cancers through blood samples. The ability to detect cancer sooner not only improves patient outcomes but also boosts demand for more frequent and comprehensive biopsy testing. As a result, the market for cancer biopsies continues to grow, supported by the increasing adoption of cutting-edge diagnostic technologies.

Request Report Sample@

https://www.researchnester.com/sample-request-6572

Moreover, as R&D in oncology expands, there is a rising emphasis on detecting a broader range of cancers, including rare and less common types. This trend drives the need for specialized biopsies that can accommodate diverse tumor characteristics and varying tissue types. In January 2024, PanGIA Biotech [AD1] announced plans to develop and expand a scalable liquid biopsy technology for global impact. It further stated that it is finalizing its three-year, prospective, multicenter, clinical study on prostate cancer liquid biopsy, in addition to launching additional clinical studies for early detection of multi-cancer using the PanGIA Liquid Biopsy Platform.

Some of the major growth factors and challenges that are associated with the growth of the global cancer biopsy market are:

Growth Drivers:

·       Companion Diagnostics Development

·       Regenerative Medicine and Tumor Microenvironment Studies

Challenges:

Limited access to skilled professionals poses a significant challenge in the cancer biopsy market, as specialized expertise is required for accurate biopsy collection, handling, and interpretation. Many regions, mainly in low-resource settings, witness a shortage of trained pathologists, oncologists, and radiologists who can perform the procedures and analyze the results with precision. The lack of skilled personnel can lead to diagnostic delays, inaccuracies, and limited availability of advanced biopsy techniques, ultimately affecting timely cancer diagnosis and treatment outcomes.

By biopsy type, the global cancer biopsy market is segmented into tissue biopsy, liquid biopsy, image-guided biopsy, and other biopsy types. The tissue biopsy segment is anticipated to garner the highest revenue by the end of 2037 by growing at a significant CAGR of 8.5% over the forecast period.  This is due to its established role as the gold standard for cancer diagnosis and staging. It allows for a comprehensive analysis of tumor architecture and cellular characteristics, providing pathologists with crucial information on cancer type, grade, and molecular markers. Tissue biopsies are widely used in hospitals and diagnostic labs, ensuring they remain the preferred choice for accurate cancer diagnosis across various types of tumors.

By region, the Europe cancer biopsy market is projected to generate considerable revenue by the end of 2037. As per an article posted by the World Health O[AD2] rganization, 20% of deaths in the European region are caused by cancers. Another article by the European Commission [AD3] posted in July 2024, stated that the highest standardized death rates related to cancer were recorded in Hungary and Croatia, among the EU countries, in 2021. Owing to such rising cases, advanced healthcare infrastructure, and a strong focus on R&D activities, the region’s market is expected to flourish in the upcoming years.

This report also provides the existing competitive scenario of some of the key players of the market, including ANGLE plc, BD (Becton, Dickinson and Company), Biodesix (Integrated Diagnostics), Chronix Biomedical, Inc (Oncocyte Corporation), Devicor Medical Products, Inc., and others.

Access our detailed report at:

https://www.researchnester.com/reports/cancer-biopsy-market/6572

Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties.

Contact for more Info:

AJ Daniel

Email: info@researchnester.com

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919